1 August 2015

Contents

Editorial

• July/Aug 2015: Volume 16 Number 7/8

In memory

• Tribute to Bob Munk: long-time HIV positive US treatment activist and educator

Conference reports

• 8th IAS Conference on HIV Pathogenesis, Treatment and Prevention (IAS 2015), 19 – 22 July 2015, Vancouver, Canada

• Four reasons IAS 2015 will be a milestone HIV conference: a personal view

• Starting HIV treatment at high CD4 counts protects against both AIDS and non-AIDS events: overall and in subgroup analyses of START study

• The option for same day antiretroviral therapy on diagnosis: the future model for HIV care

• Pipeline ARVs at IAS 2015: doravirine, BMS-955176 and BMS-663068

• New directions in the 2015 WHO ART guidelines

• Rapid implementation of the 2013 WHO ART guidelines

• Large variation across countries in meeting UNAIDS 90-90-90 targets

• Low dose boosted atazanavir is non-inferior to standard dose in Thai treatment optimisation study: LASA

• HPTN 052: no HIV transmissions on effective ART but only limited data on viral failure and drug resistance

• Dispersible tablet formulation of dolutegravir is bioequivalent to the granule formulation

• New case of remission in a perinatally infected teenager

• IAS 2015: accessing webcasts and abstracts online

• IAS Towards an HIV Cure symposium, 18 – 19 July 2015, Vancouver, Canada

• Plenary talks at IAS Cure Workshop

Antiretrovirals

• Rilpivirine/FTC/TAF becomes the third TAF-based fixed dose combination submitted for US approval

Treatment access

• “We will win or lose the fight against AIDS in next five years”: UNAIDS and Lancet commission report

Guidelines

• Draft BHIVA treatment guidelines (2015): the most significant changes for a decade

Hepatitis coinfection

• Comprehensive review of DAA research at EASL

Cure-related research

• Innate immunity and HIV DNA declines in panobinostat recipients

On the web

• RITA online: feature on bone health

• Involving people in services: a guide to why and how

PDFs

• July/August 2015: Volume 16 Number 7/8